Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has ...
A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...
Arcturus Therapeutics (ARCT) stock falls as Citi downgrades the company following weak mid-stage trial data for its cystic ...
Helping certain genetic information travel to specific parts of nerve cells can ease motor symptoms in SMA, a study in mice ...
PreliminaryResultsYield43%OverallResponseRates(viaRECIST)intheEfficacyPopulationDataDemonstrateREM-422,theFirst-in-ClassSmallMoleculeMYBmRNADegrad ...
Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...
Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients ...
Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...
Investor's Business Daily on MSN
Arcturus Crashes 50% On 'Underwhelming' Results For mRNA-Tied Cystic Fibrosis Drug
Shares of Arcturus Therapeutics crashed more than 50% early Wednesday on mixed test results for its experimental cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback